Logo

PRTC

PureTech Health plc

PRTC

PureTech Health plc • NASDAQ
$16.70 ▲ 4.38% (+0.70)
Market Cap $403.61 M
52w High $23.69
52w Low $13.30
Dividend Yield 0%
P/E 9.82
Volume 3.44K
Outstanding Shares 24.17M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $1.851M ▼ $24.882M ▼ $-44.605M ▼ -2.41K% ▼ $-1.9 ▼ $-46.24M ▼
Q4-2024 $4.027M ▲ $112.652M ▲ $95.283M ▲ 2.366K% ▲ $3.5 ▲ $101.966M ▲
Q2-2024 $288K ▲ $27.758M ▼ $-41.773M ▼ -14.505K% ▲ $-1.5 ▼ $-64.584M ▼
Q4-2023 $178.569K ▼ $67.803M ▼ $-40.369M ▼ -22.607K% ▼ $-0.74 ▼ $-11.167M ▲
Q2-2023 $3.15M $76.251M $-25.005M -793.81% $-0.45 $-36.55M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $321.551M ▼ $553.242M ▼ $184.217M ▼ $375.975M ▼
Q4-2024 $367.307M ▼ $602.635M ▲ $194.702M ▼ $414.707M ▲
Q2-2024 $500.416M ▲ $579.95M ▼ $273.744M ▲ $315.867M ▼
Q4-2023 $327.143M ▼ $693.973M ▲ $235.742M ▲ $464.066M ▼
Q2-2023 $352.139M $693.552M $184.661M $513.669M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-44.605M ▼ $-46.337M ▲ $29.934M ▲ $-3.806M ▼ $-20.035M ▲ $-45.942M ▲
Q4-2024 $69.555M ▲ $-53.003M ▲ $1.951M ▼ $22.314M ▲ $-27.831M ▼ $-54.366M ▲
Q2-2024 $-41.773M ▲ $-80.014M ▼ $236.512M ▲ $-39.101M ▼ $117.405M ▲ $-80.014M ▼
Q4-2023 $-65.697M ▼ $-39.942M ▲ $-105.442M ▼ $-14.377M ▼ $-159.43M ▼ $-40.115M ▲
Q2-2023 $-25.005M $-65.133M $173.885M $91.897M $200.149M $-65.203M

Five-Year Company Overview

Income Statement

Income Statement PureTech is still very much a development‑stage biotech story. Reported revenue is essentially non‑existent, which is typical for a company that has not yet brought products to market and instead focuses on R&D and creating spin‑out entities. Operating results show recurring losses from running the business and funding research, again normal for this model. However, bottom‑line results have been quite volatile, flipping between profit and loss. That volatility likely reflects one‑off gains and proceeds from stakes in founded companies, rather than a stable, repeatable earnings base. In other words, today’s income statement is driven more by transactions and investments than by a core commercial franchise.

Balance Sheet

Balance Sheet The balance sheet looks relatively conservative for a biotech. Total assets have come down over the past several years, which suggests they have been using their resources to fund operations and pipeline development. Cash remains a meaningful portion of total assets, giving them some flexibility to keep advancing programs. Debt levels are very low relative to the size of the company, and equity still represents the bulk of the capital structure. This points to a business that has largely avoided heavy borrowing and instead relies on equity and asset monetization. The gradual erosion of equity over time reflects ongoing losses, but not an over‑leveraged balance sheet.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, which is expected for a biotech that is investing in clinical trials and platform development without commercial products. Free cash flow closely tracks operating cash flow because capital spending needs are modest. This pattern means the company depends on external sources of cash—such as proceeds from stakes in founded entities, partnerships, or capital raises—to keep funding its pipeline. The cash burn appears deliberate and focused on R&D, but it underlines that the current business is not self‑funding and remains sensitive to financing conditions and monetization events.

Competitive Edge

Competitive Edge PureTech’s competitive strength comes less from current sales and more from its structure and ecosystem. The “hub‑and‑spoke” model lets it incubate many programs, then spin the most promising into separate companies that attract outside capital. This spreads scientific and financial risk across multiple shots on goal instead of one or two flagship drugs. The company’s track record with Karuna and other founded entities validates this approach and helps attract partners, talent, and investors. At the same time, PureTech still faces the intense competition, scientific uncertainty, and regulatory hurdles that all biotechs do. Its edge lies in portfolio breadth, capital‑efficient development, and retained economic interests in spun‑out successes, rather than in a single dominant product.

Innovation and R&D

Innovation and R&D Innovation is the core of PureTech’s story. The Glyph platform for lymphatic‑targeted oral delivery, the Alivio inflammation‑responsive system, and its work on deuterated drugs all aim to make existing therapeutic concepts more effective, more convenient, or better tolerated. These are platform‑type technologies that can support multiple drug candidates across different diseases. The pipeline is broad, with late‑stage assets like LYT‑100 and earlier‑stage programs in oncology, neurology, inflammation, and rare diseases, plus digital health initiatives such as voice‑based AI. This breadth offers many potential value drivers but also brings execution risk: clinical setbacks or delays in any of the major programs could affect sentiment and future funding. Overall, R&D is clearly sophisticated and ambitious, but outcomes remain tied to clinical trial success.

Summary

PureTech looks like a classic, high‑innovation, asset‑rich but earnings‑light biotech platform company. Its financial statements show limited recurring revenue, ongoing operating losses, and negative cash flow, all driven by heavy investment in R&D and in its hub‑and‑spoke structure. The balance sheet is relatively clean, with low debt and a meaningful cash base, but resources have been drawn down over time to support development. Strategically, the company’s edge is its ability to generate multiple, diversified programs and spin them into separate entities while retaining economic upside. Past successes lend credibility to this model and provide non‑dilutive funding, but future value still hinges on successful trials, regulatory approvals, and monetization events. In short, PureTech is positioned as an innovation engine with a diversified pipeline and a capital‑efficient structure, but it remains firmly in the high‑risk, development‑stage phase where scientific and funding uncertainties are central.

NEWS

October 22, 2025 · 2:00 AM UTC

PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group

Read more

September 29, 2025 · 2:00 AM UTC

PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF

Read more